A proof-of-concept Phase II study is being carried out in the US to analyse the safety, efficacy and tolerability of EVT 101 in patients with treatment-resistant depression (TRD).

EVT 101, developed by Evotec AG, is an orally available NR2B subtype selective NMDA receptor antagonist – an alternative to improve depression in patients resistant to conventional antidepressants.

The study is expected to confirm the treatment-resistance of the 100 patients involved in a prospective 6-week antidepressant-treatment phase, preceding the actual 4-week double-blind trial.

The study is being conducted by Germany-based Evotec AG and Switzerland-based Roche.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData